inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 110.35401/2541-9897-2026-11-2-132-139inovmed-1540Research ArticleОБЗОРЫREVIEWSФоллистатин-подобный белок-1 и сердечно-сосудистые заболеванияFollistatin-Like Protein 1 and Cardiovascular Diseaseshttps://orcid.org/0000-0001-5416-8579АлиеваА. М.AlievaA. M.

Алиева Амина Магомедовна, к. м. н., доцент кафедры госпитальной терапии им. акад. Г.И. Сторожакова.

117997, Москва, ул. Островитянова, 1

Amina M. Alieva - Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy named after Academician G.I. Storozhakova.

1 Ostrovityanova St., Moscow, 117997

amisha_alieva@mail.ruhttps://orcid.org/0000-0003-0886-6290БайковаИ. Е.BaykovaI. E.

Байкова Ирина Евгеньевна - к. м. н., доцент кафедры госпитальной терапии им. акад. Г.И. Сторожакова.

Москва

Irina E. Baykova - Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy named after Academician G.I. Storozhakova.

Moscow

https://orcid.org/0009-0008-4194-8486СултангалиеваА. Б.SultangalievaA. B.

Султангалиева Альбина Булатовна - студент 6-го курса.

Москва

Albina B. Sultangalieva - 6th year Student.

Moscow

https://orcid.org/0000-0003-1699-0881НикитинИ. Г.NikitinI. G.

Никитин Игорь Геннадиевич - д. м. н., профессор, заведующий кафедрой госпитальной терапии им. акад. Г.И. Сторожакова.

Москва

Igor G. Nikitin - Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy named after Academician G.I. Storozhakova.

Moscow

Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian Federation202622052026112132139Copyright © Алиева А.М., Байкова И.Е., Султангалиева А.Б., Никитин И.Г., 20262026Алиева А.М., Байкова И.Е., Султангалиева А.Б., Никитин И.Г.Alieva A.M., Baykova I.E., Sultangalieva A.B., Nikitin I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/1540

Данный литературный обзор подчеркивает важность определения уровня фоллистатиноподобного белка-1 для диагностических целей и прогнозирования заболеваний. Предполагается, что дальнейшие научные и клинические исследования продемонстрируют оправданность его включения в число лабораторных показателей, используемых для постановки диагноза и прогностической оценки состояния больных сердечно-сосудистыми заболеваниями. Контроль над концентрацией и экспрессией фоллистатиноподобного белка-1 представляет собой многообещающий подход к терапии кардиоваскулярной патологии.

This literature review highlights the importance of assessing follistatin-like protein 1 levels for diagnostic and prognostic purposes. It is anticipated that future scientific and clinical studies will confirm the feasibility as an adjunct laboratory tool for diagnosis and prognosis evaluation in patients with cardiovascular diseases. Modulation of the concentration and expression of follistatin-like protein 1 may represent a promising therapeutic approach in the management of cardiovascular pathology.

сердечно-сосудистые заболеваниябиологический маркерфоллистатин-подобный белок-1cardiovascular diseasesbiological markerfollistatin-like protein 1ReferencesAhmadzadeh AM, Khodashahi R, Shabestari MM, et al. The Association between Serum Follistatin-like Proteins and Cardiovascular Diseases: A Systematic Review and Meta-analysis. Curr Cardiol Rev. 2024;20(6):e180724231994. PMID: 39034719. PMCID: PMC11440331. https://doi.org/10.2174/011573403X304195240715103930Ahmadzadeh AM, Khodashahi R, Shabestari MM, et al. The Association between Serum Follistatin-like Proteins and Cardiovascular Diseases: A Systematic Review and Meta-analysis. Curr Cardiol Rev. 2024;20(6):e180724231994. PMID: 39034719. PMCID: PMC11440331. https://doi.org/10.2174/011573403X304195240715103930Алиева А.М., Теплова Н.В., Батов М.А. и др. Пентраксин-3 – перспективный биологический маркер при сердечной недостаточности: литературный обзор. Consilium Medicum. 2022;24(1):53-59. https://doi.org/10.26442/20751753.2022.1.201382Alieva AM, Teplova NV, Batov MA, et al. Pentraxin-3 – a promising biological marker in heart failure: literature review. Consilium Medicum. 2022;24(1):53–59. (In Russ.). https://doi.org/ 10.26442/20751753.2022.1.201382Алиева А.М., Байкова И.Е., Резник Е.В. и др. Сердечный белок, связывающий жирные кислоты, – перспективный биологический маркер при сердечной недостаточности. РМЖ. Медицинское обозрение. 2022;6(1):5-11. https://doi.org/10.32364/2587-6821-2022-6-1-5-11Alieva AM, Baykova IE, Reznik EV, et al. Heart-type fatty acid binding protein: the promising biological marker in heart failure. Russian Medical Inquiry. 2022;6(1):5–11 (In Russ.). https://doi.org/10.32364/2587-6821-2022-6-1-5-11Horak M, Fairweather D, Kokkonen P, et al. Follistatinlike 1 and its paralogs in heart development and cardiovascular disease. Heart Fail Rev. 2022;27(6):2251-2265. PMID: 35867287. PMCID: PMC11140762. https://doi.org/10.1007/s10741-022-10262-6Horak M, Fairweather D, Kokkonen P, et al. Follistatinlike 1 and its paralogs in heart development and cardiovascular disease. Heart Fail Rev. 2022;27(6):2251-2265. PMID: 35867287. PMCID: PMC11140762. https://doi.org/10.1007/s10741-022-10262-6Karisa P, Sylviana N, Fitria N, et al. FSTL-1 as a Novel Cardiokine of Cardiac Angiogenesis: A Systematic Review. Vasc Health Risk Manag. 2025;21:437-449. PMID: 40453420. PMCID: PMC12126109. https://doi.org/10.2147/VHRM.S509482Karisa P, Sylviana N, Fitria N, et al. FSTL-1 as a Novel Cardiokine of Cardiac Angiogenesis: A Systematic Review. Vasc Health Risk Manag. 2025;21:437-449. PMID: 40453420. PMCID: PMC12126109. https://doi.org/10.2147/VHRM.S509482Bielka W, Przezak A, Pawlik A. Follistatin and follistatinlike 3 in metabolic disorders. Prostaglandins Other Lipid Mediat. 2023;169:106785. PMID: 37739334. https://doi.org/10.1016/j.prostaglandins.2023.106785Bielka W, Przezak A, Pawlik A. Follistatin and follistatinlike 3 in metabolic disorders. Prostaglandins Other Lipid Mediat. 2023;169:106785. PMID: 37739334. https://doi.org/10.1016/j.prostaglandins.2023.106785Gao Y, Ren J, Peng H, et al. Follistatin-like protein 1: Implications for renal disease progression. J Pharmacol Exp Ther. 2025;392(5):103564. PMID: 40239460. https://doi.org/10.1016/j.jpet.2025.103564Gao Y, Ren J, Peng H, et al. Follistatin-like protein 1: Implications for renal disease progression. J Pharmacol Exp Ther. 2025;392(5):103564. PMID: 40239460. https://doi.org/10.1016/j.jpet.2025.103564Mattiotti A, Prakash S, Barnett P, et al. Follistatinlike 1 in development and human diseases. Cell Mol Life Sci. 2018;75(13):2339-2354. PMID: 29594389. PMCID: PMC5986856. https://doi.org/10.1007/s00018-018-2805-0Mattiotti A, Prakash S, Barnett P, et al. Follistatinlike 1 in development and human diseases. Cell Mol Life Sci. 2018;75(13):2339-2354. PMID: 29594389. PMCID: PMC5986856. https://doi.org/10.1007/s00018-018-2805-0Gu C, Xue H, Yang X, et al. Role of follistatin-like protein 1 in liver diseases. Exp Biol Med (Maywood). 2023;248(3):193200. PMID: 36533576. PMCID: PMC10107393. https://doi.org/10.1177/15353702221142604Gu C, Xue H, Yang X, et al. Role of follistatin-like protein 1 in liver diseases. Exp Biol Med (Maywood). 2023;248(3):193200. PMID: 36533576. PMCID: PMC10107393. https://doi.org/10.1177/15353702221142604Sylva M, Li VS, Buffing AA, et al. The BMP antagonist follistatin-like 1 is required for skeletal and lung organogenesis. PLoS One. 2011;6(8):e22616. PMID: 21826198. PMCID: PMC3149603. https://doi.org/10.1371/journal.pone.0022616Sylva M, Li VS, Buffing AA, et al. The BMP antagonist follistatin-like 1 is required for skeletal and lung organogenesis. PLoS One. 2011;6(8):e22616. PMID: 21826198. PMCID: PMC3149603. https://doi.org/10.1371/journal.pone.0022616Okabayashi K, Shoji H, Onuma Y, et al. cDNA cloning and distribution of the Xenopus follistatin-related protein. Biochem Biophys Res Commun. 1999;254(1):42-8. PMID: 9920730. https://doi.org/10.1006/bbrc.1998.9892Okabayashi K, Shoji H, Onuma Y, et al. cDNA cloning and distribution of the Xenopus follistatin-related protein. Biochem Biophys Res Commun. 1999;254(1):42-8. PMID: 9920730. https://doi.org/10.1006/bbrc.1998.9892Pontemezzo E, Foglio E, Vernucci E, et al. miR-200c-3p Regulates Epitelial-to-Mesenchymal Transition in Epicardial Mesothelial Cells by Targeting Epicardial Follistatin-Related Protein 1. Int J Mol Sci. 2021;22(9):4971. PMID: 34067060. PMCID: PMC8125323. https://doi.org/10.3390/ijms22094971Pontemezzo E, Foglio E, Vernucci E, et al. miR-200c-3p Regulates Epitelial-to-Mesenchymal Transition in Epicardial Mesothelial Cells by Targeting Epicardial Follistatin-Related Protein 1. Int J Mol Sci. 2021;22(9):4971. PMID: 34067060. PMCID: PMC8125323. https://doi.org/10.3390/ijms22094971Alteköester AK, Harvey RP. Bioengineered FSTL1 Patches Restore Cardiac Function Following Myocardial Infarction. Trends Mol Med. 2015;21(12):731-733. PMID: 26596868. https://doi.org/10.1016/j.molmed.2015.10.006Alteköester AK, Harvey RP. Bioengineered FSTL1 Patches Restore Cardiac Function Following Myocardial Infarction. Trends Mol Med. 2015;21(12):731-733. PMID: 26596868. https://doi.org/10.1016/j.molmed.2015.10.006Seki M, Powers JC, Maruyama S, et al. Acute and Chron ic Increases of Circulating FSTL1 Normalize Energy Substrate Metabolism in Pacing-Induced Heart Failure. Circ Heart Fail. 2018;11(1): e004486. PMID: 29317401. PMCID: PMC5765881. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004486Seki M, Powers JC, Maruyama S, et al. Acute and Chron ic Increases of Circulating FSTL1 Normalize Energy Substrate Metabolism in Pacing-Induced Heart Failure. Circ Heart Fail. 2018;11(1): e004486. PMID: 29317401. PMCID: PMC5765881. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004486Prakash S, Borreguero LJJ, Sylva M, et al. Deletion of Fstl1 (Follistatin-Like 1) From the Endocardial/Endothelial Lineage Causes Mitral Valve Disease. Arterioscler Thromb Vasc Biol. 2017;37(9):e116-e130. PMID: 28705792. https://doi.org/10.1161/ATVBAHA.117.309089Prakash S, Borreguero LJJ, Sylva M, et al. Deletion of Fstl1 (Follistatin-Like 1) From the Endocardial/Endothelial Lineage Causes Mitral Valve Disease. Arterioscler Thromb Vasc Biol. 2017;37(9):e116-e130. PMID: 28705792. https://doi.org/10.1161/ATVBAHA.117.309089Zhao Y, Sun J, Zhang W, et al. Follistatin-Like 1 Protects against Doxorubicin-Induced Cardiomyopathy through Upregulation of Nrf2. Oxid Med Cell Longev. 2020;2020: 3598715. PMID: 32831995. PMCID: PMC7421745. https://doi.org/10.1155/2020/3598715Zhao Y, Sun J, Zhang W, et al. Follistatin-Like 1 Protects against Doxorubicin-Induced Cardiomyopathy through Upregulation of Nrf2. Oxid Med Cell Longev. 2020;2020: 3598715. PMID: 32831995. PMCID: PMC7421745. https://doi.org/10.1155/2020/3598715Parfenova EV, Zubkova ES, Boldyreva MA, et al. Study of the influence of etoxidol on expression of follistatin-like protein-1 (FSTL-1) in myocardium after experimental infarction in rats. Biomed Khim. 2020;66(3):250-256. PMID: 32588831. https://doi.org/10.18097/PBMC20206603250Parfenova EV, Zubkova ES, Boldyreva MA, et al. Study of the influence of etoxidol on expression of follistatin-like protein-1 (FSTL-1) in myocardium after experimental infarction in rats. Biomed Khim. 2020;66(3):250-256. PMID: 32588831. https://doi.org/10.18097/PBMC20206603250Li JP, He WB, Xu SW, et al. FSTL1 protects against acute aortic dissection by suppressing vascular smooth muscle cell phenotypic switching and degradation of the extracellular matrix. J Mol Cell Cardiol. 2025;198:60-73. PMID: 39631359. https://doi.org/10.1016/j.yjmcc.2024.11.008Li JP, He WB, Xu SW, et al. FSTL1 protects against acute aortic dissection by suppressing vascular smooth muscle cell phenotypic switching and degradation of the extracellular matrix. J Mol Cell Cardiol. 2025;198:60-73. PMID: 39631359. https://doi.org/10.1016/j.yjmcc.2024.11.008Liu H, Li Y, Li M, et al. Follistatin-like 1 protects endo thelial function in the spontaneously hypertensive rat by inhibition of endoplasmic reticulum stress through AMPK-dependent mechanism. Clin Exp Hypertens. 2023;45(1):2277654. PMID: 37963199. https://doi.org/10.1080/10641963.2023.2277654Liu H, Li Y, Li M, et al. Follistatin-like 1 protects endo thelial function in the spontaneously hypertensive rat by inhibition of endoplasmic reticulum stress through AMPK-dependent mechanism. Clin Exp Hypertens. 2023;45(1):2277654. PMID: 37963199. https://doi.org/10.1080/10641963.2023.2277654Shimano M, Ouchi N, Nakamura K, et al. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc Natl Acad Sci U S A. 2011;108(43):E899-906. PMID: 21987816. PMCID: PMC3203781. https://doi.org/10.1073/pnas.1108559108Shimano M, Ouchi N, Nakamura K, et al. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc Natl Acad Sci U S A. 2011;108(43):E899-906. PMID: 21987816. PMCID: PMC3203781. https://doi.org/10.1073/pnas.1108559108Li KS, Jiang WP, Li QC, et al. MiR-29a in mesenchymal stem cells inhibits FSTL1 secretion and promotes cardiac myocyte apoptosis in hypoxia-reoxygenation injury. Cardiovasc Pathol. 2020;46:107180. PMID: 31945680. https://doi.org/10.1016/j.carpath.2019.107180Li KS, Jiang WP, Li QC, et al. MiR-29a in mesenchymal stem cells inhibits FSTL1 secretion and promotes cardiac myocyte apoptosis in hypoxia-reoxygenation injury. Cardiovasc Pathol. 2020;46:107180. PMID: 31945680. https://doi.org/10.1016/j.carpath.2019.107180Xiao Y, Zhang Y, Chen Y, et al. Inhibition of MicroRNA9-5p Protects Against Cardiac Remodeling Following Myocardial Infarction in Mice. Hum Gene Ther. 2019;30(3):286-301. https://doi.org/10.1089/hum.2018.059. Epub 2018 Oct 31. Erratum in: Hum Gene Ther. 2023;34(13-14):664. https://doi.org/10.1089/hum.2018.059.correx. Erratum in: J Med Food. 2024;27(2):210. PMID: 30101604. https://doi.org/10.1089/jmf.2022.0091.correxXiao Y, Zhang Y, Chen Y, et al. Inhibition of MicroRNA9-5p Protects Against Cardiac Remodeling Following Myocardial Infarction in Mice. Hum Gene Ther. 2019;30(3):286-301. https://doi.org/10.1089/hum.2018.059. Epub 2018 Oct 31. Erratum in: Hum Gene Ther. 2023;34(13-14):664. https://doi.org/10.1089/ hum.2018.059.correx. Erratum in: J Med Food. 2024;27(2):210. PMID: 30101604. https://doi.org/10.1089/jmf.2022.0091.correxMaruyama S, Nakamura K, Papanicolaou KN, et al. Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture. EMBO Mol Med. 2016;8(8):949-66. PMID: 27234440. PMCID: PMC4967946. https://doi.org/10.15252/emmm.201506151Maruyama S, Nakamura K, Papanicolaou KN, et al. Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture. EMBO Mol Med. 2016;8(8):949-66. PMID: 27234440. PMCID: PMC4967946. https://doi.org/10.15252/emmm.201506151Peters MC, Di Martino S, Boelens T, et al. Follistatinlike 1 promotes proliferation of matured human hypoxic iPSC-cardiomyocytes and is secreted by cardiac fibroblasts. Mol Ther Methods Clin Dev. 2022;25:3-16. PMID: 35317048. PMCID: PMC8917270. https://doi.org/10.1016/j.omtm.2022.02.005Peters MC, Di Martino S, Boelens T, et al. Follistatinlike 1 promotes proliferation of matured human hypoxic iPSCcardiomyocytes and is secreted by cardiac fibroblasts. Mol Ther Methods Clin Dev. 2022;25:3-16. PMID: 35317048. PMCID: PMC8917270. https://doi.org/10.1016/j.omtm.2022.02.005Arrigoni R, Jirillo E, Caiati C. Pathophysiology of Doxorubicin-Mediated Cardiotoxicity. Toxics. 2025;13(4):277. PMID: 40278593. PMCID: PMC12031459. https://doi.org/10.3390/toxics13040277Arrigoni R, Jirillo E, Caiati C. Pathophysiology of Doxorubicin-Mediated Cardiotoxicity. Toxics. 2025;13(4):277. PMID: 40278593. PMCID: PMC12031459. https://doi.org/10.3390/toxics13040277Lu Y, Yang J, Wu Q, et al. The Role and Molecular Pathways of SIRT6 in Senescence and Age-related Diseases. Adv Biol (Weinh). 2025;9(4):e2400469. PMID: 39913122. https://doi.org/10.1002/adbi.202400469Lu Y, Yang J, Wu Q, et al. The Role and Molecular Pathways of SIRT6 in Senescence and Age-related Diseases. Adv Biol (Weinh). 2025;9(4):e2400469. PMID: 39913122. https://doi.org/10.1002/adbi.202400469Xu H, Guo H, Tang Z, et al. Follistatin-like 1 protects against doxorubicin-induced cardiotoxicity by preventing mitochondrial dysfunction through the SIRT6/Nrf2 signaling pathway. Cell Biol Int. 2024;48(6):795-807. PMID: 38436106. https://doi.org/10.1002/cbin.12147Xu H, Guo H, Tang Z, et al. Follistatin-like 1 protects against doxorubicin-induced cardiotoxicity by preventing mitochondrial dysfunction through the SIRT6/Nrf2 signaling pathway. Cell Biol Int. 2024;48(6):795-807. PMID: 38436106. https://doi.org/10.1002/cbin.12147Lu L, Shao Y, Wang N, et al. Follistatin-like protein 1 attenuates doxorubicin-induced cardiomyopathy by inhibiting MsrB2mediated mitophagy. Mol Cell Biochem. 2024;479(7):1817-1831. PMID: 38696001. https://doi.org/10.1007/s11010-024-04955-9Lu L, Shao Y, Wang N, et al. Follistatin-like protein 1 attenuates doxorubicin-induced cardiomyopathy by inhibiting MsrB2mediated mitophagy. Mol Cell Biochem. 2024;479(7):1817-1831. PMID: 38696001. https://doi.org/10.1007/s11010-024-04955-9Shen H, Cui G, Li Y, et al. Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model. Stem Cell Res Ther. 2019;10(1):17. https://doi.org/10.1186/s13287-0181111-y. Erratum in: Stem Cell Res Ther. 2024;15(1):47. PMID: 30635025. PMCID: PMC6330478. https://doi.org/10.1186/s13287024-03662-yShen H, Cui G, Li Y, et al. Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model. Stem Cell Res Ther. 2019;10(1):17. https://doi.org/10.1186/s13287-0181111-y. Erratum in: Stem Cell Res Ther. 2024;15(1):47. PMID: 30635025. PMCID: PMC6330478. https://doi.org/10.1186/s13287024-03662-yMagadum A, Singh N, Kurian AA, et al. Ablation of a Single N-Glycosylation Site in Human FSTL 1 Induces Cardiomyocyte Proliferation and Cardiac Regeneration. Mol Ther Nucleic Acids. 2018;13:133-143. PMID: 30290305. PMCID: PMC6171324. https://doi.org/10.1016/j.omtn.2018.08.021Magadum A, Singh N, Kurian AA, et al. Ablation of a Single N-Glycosylation Site in Human FSTL 1 Induces Cardiomyocyte Proliferation and Cardiac Regeneration. Mol Ther Nucleic Acids. 2018;13:133-143. PMID: 30290305. PMCID: PMC6171324. https://doi.org/10.1016/j.omtn.2018.08.021Wang HB, Huang R, Yang K, et al. Identification of differentially expressed genes and preliminary validations in cardiac pathological remodeling induced by transverse aortic constriction. Int J Mol Med. 2019;44(4):1447-1461. PMID: 31364721. PMCID: PMC6713409. https://doi.org/10.3892/ijmm.2019.4291Wang HB, Huang R, Yang K, et al. Identification of differentially expressed genes and preliminary validations in cardiac pathological remodeling induced by transverse aortic constriction. Int J Mol Med. 2019;44(4):1447-1461. PMID: 31364721. PMCID: PMC6713409. https://doi.org/10.3892/ijmm.2019.4291Pahlavani HA. Exercise-induced signaling pathways to counteracting cardiac apoptotic processes. Front Cell Dev Biol. 2022;10:950927. PMID: 36036015. PMCID: PMC9403089. https://doi.org/10.3389/fcell.2022.950927Pahlavani HA. Exercise-induced signaling pathways to counteracting cardiac apoptotic processes. Front Cell Dev Biol. 2022;10:950927. PMID: 36036015. PMCID: PMC9403089. https://doi.org/10.3389/fcell.2022.950927Xi Y, Hao M, Liang Q, et al. Dynamic resistance exercise increases skeletal muscle-derived FSTL1 inducing cardiac angiogenesis via DIP2ASMAD2/3 in rats following myocardial infarction. J Sport Health Sci. 2021;10(5):594-603. PMID: 33246164. PMCID: PMC8500809. https://doi.org/10.1016/j.jshs.2020.11.010Xi Y, Hao M, Liang Q, et al. Dynamic resistance exercise increases skeletal muscle-derived FSTL1 inducing cardiac angiogenesis via DIP2ASMAD2/3 in rats following myocardial infarction. J Sport Health Sci. 2021;10(5):594-603. PMID: 33246164. PMCID: PMC8500809. https://doi.org/10.1016/j.jshs.2020.11.010Hu S, Liu H, Hu Z, et al. Follistatin-like 1: A dual regulator that promotes cardiomyocyte proliferation and fibrosis. J Cell Physiol. 2020;235(9):5893-5902. PMID: 32017077. https://doi.org/10.1002/jcp.29588Hu S, Liu H, Hu Z, et al. Follistatin-like 1: A dual regulator that promotes cardiomyocyte proliferation and fibrosis. J Cell Physiol. 2020;235(9):5893-5902. PMID: 32017077. https://doi.org/10.1002/jcp.29588Ponce-Ruíz N, Herrera-Moreno JF, Rojas-García AE, et al. Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population. Heart Vessels. 2024;39(6):563-570. PMID: 38381171. https://doi.org/10.1007/s00380-024-02364-yPonce-Ruíz N, Herrera-Moreno JF, Rojas-García AE, et al. Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population. Heart Vessels. 2024;39(6):563-570. PMID: 38381171. https://doi.org/10.1007/s00380-024-02364-yWidera C, Giannitsis E, Kempf T, et al. Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome. Clin Chem. 2012;58(8):1233-41. PMID: 22675198. PMCID: PMC3539794.https://doi.org/10.1373/clinchem.2012.182816Widera C, Giannitsis E, Kempf T, et al. Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome. Clin Chem. 2012;58(8):1233-41. PMID: 22675198. PMCID: PMC3539794.https://doi.org/10.1373/clinchem.2012.182816Tanaka K, Valero-Muñoz M, Wilson RM, et al. Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction. JACC Basic Transl Sci. 2016;1(4):207221. PMID: 27430031. PMCID: PMC4944656. https://doi.org/10.1016/j.jacbts.2016.04.002Tanaka K, Valero-Muñoz M, Wilson RM, et al. Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction. JACC Basic Transl Sci. 2016;1(4):207221. PMID: 27430031. PMCID: PMC4944656. https://doi.org/10.1016/j.jacbts.2016.04.002Uematsu M, Nakamura K, Nakamura T, et al. Persistent Myocardial Production of Follistatin-like 1 Is Associated with Left Ventricular Adverse Remodeling in Patients with Myocardial Infarction: Myocardial production of FSTL1 in AMI patients. J Card Fail. 2020;26(8):733-738. PMID: 32470377. https://doi.org/10.1016/j.cardfail.2020.05.015Uematsu M, Nakamura K, Nakamura T, et al. Persistent Myocardial Production of Follistatin-like 1 Is Associated with Left Ventricular Adverse Remodeling in Patients with Myocardial Infarction: Myocardial production of FSTL1 in AMI patients. J Card Fail. 2020;26(8):733-738. PMID: 32470377. https://doi.org/10.1016/j.cardfail.2020.05.015Aikawa T, Shimada K, Miyauchi K, et al. Associations among circulating levels of follistatin-like 1, clinical parameters, and cardiovascular events in patients undergoing elective percutaneous coronary intervention with drug-eluting stents. PLoS One. 2019;14(4):e0216297. PMID: 31034503. PMCID: PMC6488088. https://doi.org/10.1371/journal.pone.0216297Aikawa T, Shimada K, Miyauchi K, et al. Associations among circulating levels of follistatin-like 1, clinical parameters, and cardiovascular events in patients undergoing elective percutaneous coronary intervention with drug-eluting stents. PLoS One. 2019;14(4):e0216297. PMID: 31034503. PMCID: PMC6488088. https://doi.org/10.1371/journal.pone.0216297El-Armouche A, Ouchi N, Tanaka K, et al. Follistatinlike 1 in chronic systolic heart failure: a marker of left ventricular remodeling. Circ Heart Fail. 2011;4(5):621-7. PMID: 21622850. PMCID: PMC3178753. https://doi.org/10.1161/CIRCHEARTFAILURE.110.960625El-Armouche A, Ouchi N, Tanaka K, et al. Follistatinlike 1 in chronic systolic heart failure: a marker of left ventricular remodeling. Circ Heart Fail. 2011;4(5):621-7. PMID: 21622850. PMCID: PMC3178753. https://doi.org/10.1161/CIRCHEARTFAILURE.110.960625Lee SY, Kim DY, Kyung Kwak M, et al. High circulating follistatin-like protein 1 as a biomarker of a metabolically unhealthy state. Endocr J. 2019;66(3):241-251. PMID: 30745500. https://doi.org/10.1507/endocrj.EJ18-0352Lee SY, Kim DY, Kyung Kwak M, et al. High circulating follistatin-like protein 1 as a biomarker of a metabolically unhealthy state. Endocr J. 2019;66(3):241-251. PMID: 30745500. https://doi.org/10.1507/endocrj.EJ18-0352

The authors declare that there are no conflicts of interest present.